The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles
Frontiers in Immunology, 2022 Sharks and other cartilaginous fish produce new antigen receptor (IgNAR) antibodies, as key part of their humoral immune response and are the phylogenetically oldest living organisms that possess an immunoglobulin (Ig)-based adaptive immune system. IgNAR
Klaus R. Liedl +2 more
exaly +5 more sources
Construction and application of a large capacity VNAR library from the whitespotted bamboo shark (Chiloscyllium playgiosum) [PDF]
Acta Pharmaceutica Sinica BFifty whitespotted bamboo sharks (Chiloscyllium playgiosum) of both sexes were used to establish a large capacity variable domain of the new antigen receptor (VNAR) library with a total capacity of over 109 colony-forming units (CFU).
Hao Li +9 more
doaj +4 more sources
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development [PDF]
Frontiers in Immunology, 2017 Molecular engineering to increase the percentage identity to common human immunoglobulin sequences of non-human therapeutic antibodies and scaffolds has become standard practice.
John Steven +11 more
doaj +6 more sources
Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. [PDF]
FASEB Journal, 2021 Abstract Single domain shark VNAR antibodies can offer a viable alternative to conventional Ig-based monoclonal antibodies in treating COVID-19 disease during the current pandemic. Here we report the identification of neutralizing single domain VNAR antibodies selected against the SARS-CoV-2 spike protein derived from
Andreas J Kungl +2 more
exaly +7 more sources
Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2 [PDF]
Frontiers in Immunology, 2023 The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a joint global effort to develop vaccines and other treatments that could mitigate the negative effects and the rapid spread of the virus.
Olivia Cabanillas-Bernal +4 more
doaj +4 more sources
Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies. [PDF]
PLoS ONECancer is the second leading cause of death worldwide. To combat this disease, novel and specialized therapeutic systems are urgently needed. This is the first study to explore a system that combines shark variable domain (Fv) of new antigen receptor ...
Lizbeth A Manzanares-Guevara +6 more
doaj +6 more sources
A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy [PDF]
Acta Pharmaceutica Sinica BTROP-2, a tumor-associated antigen, has been implicated in the progression of various epithelial tumors. Due to its favorable expression profile, TROP-2 has emerged as a promising target for antibody-drug conjugates (ADCs) based anti-tumor therapies. Although ADCs have shown efficacy in cancer treatment, their application in solid tumors is hindered by
Ming-Wei Wang, Qiang Wang, Zhicheng Zuo
exaly +4 more sources
Identification and characterization of shark VNARs targeting the Helicobacter pylori adhesin HpaA
Artificial Cells, Nanomedicine, and Biotechnology, 2023 Helicobacter pylori (H. pylori) is recognized as a pathogen associated with several gastrointestinal diseases. The current treatments exhibit numerous drawbacks, including antibiotic resistance. H.
Yanchun Gao +7 more
doaj +3 more sources
Applied Sciences, 2023 The shark-derived single-domain antibody VNAR (variable domain of new antigen receptor) has many advantageous features that make the VNAR suitable for improving current monoclonal antibody therapy deficiencies or disease diagnosis methods.
Chia-Hung Tsai +3 more
doaj +2 more sources
Theranostic vNAR-Based Immunoconjugates Achieve Selective Intracellular Cisplatin Delivery in Embedded 3D HER2-Positive Breast Cancer In Vitro Model [PDF]
PharmaceuticalsBackground/Objectives: Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy.
Andrea C. Alfonseca-Ladrón de Guevara +5 more
doaj +2 more sources